Alogliptin And Metformin Hydrochloride Tablet, Film Coated
Product Images NDC 45802-169

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alogliptin And Metformin Hydrochloride (NDC 45802-169). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Israel Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Alogliptin 01)

Chemical structure of alogliptin, one of the active ingredients in alogliptin and metformin hydrochloride tablets. The diagram shows the molecular arrangement including a bicyclic component and functional groups linked to a piperazine ring with an amino substituent.*

FDA Label Image

Chemical Structure (Alogliptin 02)

Chemical structure depicting the molecular formula of alogliptin and metformin hydrochloride, showing characteristic nitrogen, carbon, hydrogen atoms, and a hydrochloride group (HCl).*

FDA Label Image

Figure 1 (Alogliptin 03)

A pharmacokinetic interaction graph showing the ratios and 90% confidence intervals for alogliptin coadministered with various drugs across multiple enzyme and transporter substrates. The chart includes data for AUC and Cmax comparisons, concluding with recommendations of no dose adjustment. The comparison axes range from 0.6 to 1.6 for drug interaction ratios.*

FDA Label Image

Figure 2 (Alogliptin 04)

A chart presenting pharmacokinetic drug interaction data for alogliptin. It lists coadministered drugs, their dosages, and alogliptin dosages along with pharmacokinetic parameters AUC and Cmax. The graphic plots ratio and 90% confidence intervals comparing alogliptin with other drugs versus alogliptin alone, concluding with dose adjustment recommendations, all indicating no dose adjustment necessary.*

FDA Label Image

Figure 3 (Alogliptin 05)

A bar chart showing the least squares mean change in A1C (%) for placebo, alogliptin, metformin, and their combinations in various dosages. It compares baseline means and changes during treatment with alogliptin 12.5 mg twice daily, metformin 500 mg and 1000 mg twice daily, and combinations of alogliptin and metformin showing greater reductions in A1C compared to monotherapies and placebo.*

FDA Label Image

Figure 4 (Alogliptin 06)

A Kaplan-Meier cumulative event probability graph comparing outcomes for Alogliptin versus Placebo over approximately 30 months from randomization. The graph includes a hazard ratio (HR) with 98% confidence interval and a risk table showing the number of subjects at risk at various time points for both treatment groups.*

FDA Label Image

Principal Display Panel (12.5 mg/500 mg Tablet Bottle Label)

Label for alogliptin and metformin HCl tablets, film coated, 12.5 mg/500 mg strength. The label states Rx Only, includes the NDC number 45802-169-72, and notes packaging of 60 tablets. It advises dispensing with a medication guide and provides storage instructions and distributor information for Perrigo.*

FDA Label Image

Principal Display Panel (12.5 mg/1000 mg Tablet Bottle Label)

Label for Alogliptin and Metformin HCl tablets, film coated, containing 12.5 mg of alogliptin and 1000 mg of metformin hydrochloride per tablet. The package contains 60 tablets. Label shows the distributor as Perrigo, with instructions to dispense with medication guide and storage directions included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.